Viking Therapeutics Inc (VKTX.OQ)
21 Sep 2018
Viking Therapeutics Inc's shares more than doubled in value on Tuesday after promising data from a mid-stage trial of its fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals .
Sept 18 Viking Therapeutics Inc's shares more than doubled on Tuesday after its experimental liver disease treatment met the goals of a mid-stage trial by lowering cholesterol and liver fat levels in patients.
Sept 18 Viking Therapeutics Inc said on Tuesday its experimental liver disease treatment met the main goals of a mid-stage trial by reducing cholesterol and liver fat in patients.
* VIKING THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE